AJ Lanigan: Of Course. In fact, pharma providers are creating massive revenue with treatment options like Keytruda and Opdivo that offer with PD-1 and PD-L1. In this article’s the super awesome part: think of checkpoints as targeted traffic signals. You don’t want an immune method that’s managing wild just like waiting for link from Social Bookmarking (4)